Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NC-6100
- Development stage
- Unknown
- Lead developer
- NANO mRNA
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
NC-6100 is a small interfering RNA (siRNA) therapeutic developed by NANO mRNA (formerly NANO MRNA Co., Ltd.) for the treatment of solid tumors, with a primary focus on breast cancer. The drug targets PRDM14 (PR domain-containing protein 14), a transcriptional regulator that is frequently overexpressed in various cancers and plays a pivotal role in maintaining cancer stem cell populations, promoting metastasis, and conferring resistance to chemotherapy. NC-6100 utilizes a proprietary delivery system consisting of calcium phosphate (CaP) hybrid micelles. These nanoparticles are designed to protect the siRNA from degradation in the bloodstream and selectively accumulate in tumor tissues through the enhanced permeability and retention (EPR) effect. By silencing PRDM14 expression, the therapy aims to disrupt the oncogenic signaling pathways that drive tumor growth and recurrence.
- Other names
- PRDM14 siRNAPRDM-14 siRNAPRDM 14 siRNAPRDM14 siRNA successorPRDM-14 siRNA successorPRDM 14 siRNA successorPRDM14 small interfering RNAPRDM-14 small interfering RNAPRDM 14 small interfering RNA
02
Targets
KMT (Histone-lysine methyltransferases)
Beyond the preview
Go deeper on NC-6100.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NC-6100.